Australian biotech company Immutep (ASX: IMM, NASDAQ: IMMP) has delivered impressive Phase I clinical trial results for its TACTI-mel trial which has observed significant tumour size shrinkage in the majority of trial patients over the 12 month trial period. The trials tested 24 patients with melanoma which were located in areas not capable of being
Read More
Sufferers of skin conditions like acne, psoriasis and dermatitis could soon have effective cannabinoid therapeutics thanks to Botanix (ASX:BOT) and their synthetic cannabinoid trials. Presenting at the International Cannabinoid Derived Pharmaceuticals (iCDP) Summit in Boston, the presentation titled Fact or Fiction, highlighted the effectiveness seen in their recently completed clinical trials to treat acne, and
Read More
Med-tech developer ResApp Health (ASX: RAP) has received certification from European regulators for the world’s first smartphone-based respiratory diagnostics test. ResAppDx-EU is a mobile app which can be used by medical clinicians to diagnose respiratory conditions including tract disease, croup, pneumonia, asthma and bronchiolitis. “We are very excited about receiving our first regulatory approval for
Read More
With the average person’s life expectancy rising, Alzheimer’s disease is emerging as a major health concern which can have devastating effects on an individual’s cognitive function. It leads to progressive loss of brain cells which later leads to loss of memory and has become a global menace, costing the world over US$818 billion in treatment
Read More